Novavax, Inc (NASDAQ:NVAX) shares, rose in value, with the stock price up by 2.73% to the previous day’s close as strong demand from buyers drove the stock to $7.89.
Actively observing the price movement in the last trading, the stock closed the session at $7.68. Referring to stock’s 52-week performance, its high was $23.86, and the low was $3.81. On the whole, NVAX has fluctuated by -6.41% over the past month.
With the market capitalization of Novavax, Inc currently standing at about $1.27 billion, investors are eagerly awaiting this quarter’s results, scheduled for in April.
Projections by analysts suggest varying estimates for the company’s quarterly revenue. Analysts have estimated the company’s revenue for the quarter at 503.95M, with a low estimate of 31.9M and a high estimate of 106.4M. Wall Street analysts also predicted that the company’s y-o-y revenues would reach 67.7M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that NVAX’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of NVAX currently trading nearly -0.37% and -6.91% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 47.70, while the 7-day volatility ratio is showing 12.84% which for the 30-day chart, stands at 7.03%. Furthermore, Novavax, Inc (NVAX)’s beta value is 3.11, and its average true range (ATR) is 0.62.
A comparison of Novavax, Inc (NVAX) with its peers suggests the former has fared considerably weaker in the market. NVAX showed an intraday change of 2.73% in last session, and over the past year, it grew by 46.38%%. In comparison, Johnson & Johnson (JNJ) has moved lower at -0.18%% on the day and was up 3.63% over the past 12 months. On the other hand, the price of Pfizer Inc. (PFE) has risen 0.74%% on the day. The stock, however, is off -4.60% from where it was a year ago. Additionally, there is a gain of 0.68%% for Merck & Co. Inc. (MRK) in last trading while the stock has seen an overall depriciation of -24.69%% over the past year.
Data on historical trading for Novavax, Inc (NASDAQ:NVAX) indicates that the trading volumes over the past 3 months, they’ve averaged 4.29 million. According to company’s latest data on outstanding shares, there are 160.42 million shares outstanding.
Nearly 8.77% of Novavax, Inc’s shares belong to company insiders and institutional investors own 59.81% of the company’s shares. The stock has fallen by -1.87% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the NVAX stock heading into the next quarter.
